Experienced in Spinocerebellar Ataxia

Dr. John W. Day

Family Medicine | General Practice
Deblin Health Concepts And Associates, LLC
4131 Spicewood Springs Rd, Suite J1, 
Austin, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Spinocerebellar Ataxia
Deblin Health Concepts And Associates, LLC
4131 Spicewood Springs Rd, Suite J1, 
Austin, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Day is a primary care provider, practicing in Family Medicine and General Practice in Austin, Texas. Dr. Day is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia. His top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Myotonic Dystrophy Type 2, and Myotonic Dystrophy. Dr. Day is currently accepting new patients.

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Spinocerebellar Ataxia.

Specialties
Family Medicine
General Practice
Licenses
Family Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

DEBLIN HEALTH CONCEPTS AND ASSOCIATES, LLC
4131 Spicewood Springs Rd, Suite J1, Austin, TX 78759

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Enrollment Status: Recruiting
Publish Date: April 24, 2025
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth
Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth
Enrollment Status: Completed
Publish Date: October 07, 2025
A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Enrollment Status: Enrolling_by_invitation
Publish Date: July 03, 2025
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: April 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Enrollment Status: Completed
Publish Date: October 26, 2017
View 14 Less Clinical Trials

152 Total Publications

MBNL loss of function in smooth muscle as a model for myotonic dystrophy associated gastrointestinal dysmotility.
MBNL loss of function in smooth muscle as a model for myotonic dystrophy associated gastrointestinal dysmotility.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 11, 2025
Similar Doctors
Advanced in Spinocerebellar Ataxia
Dr. Ho S. Pak
Family Medicine | Internal Medicine
Advanced in Spinocerebellar Ataxia
Dr. Ho S. Pak
Family Medicine | Internal Medicine
1770 State Highway 46 W, 
New Braunfels, TX 
 (49.6 miles away)
830-730-4125
Languages Spoken:
English, Korean, Spanish
See accepted insurances
Accepting New Patients

Ho Pak is a primary care provider, practicing in Family Medicine and Internal Medicine in New Braunfels, Texas. Dr. Pak is rated as a Distinguished provider by MediFind in the treatment of Spinocerebellar Ataxia. His top areas of expertise are Spinocerebellar Ataxia Type 15, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 14, and Spinocerebellar Ataxia Type 20. Dr. Pak is currently accepting new patients.

Experienced in Spinocerebellar Ataxia
Dr. Nelly D. Velasquez
Family Medicine
Experienced in Spinocerebellar Ataxia
Dr. Nelly D. Velasquez
Family Medicine
900 E 30th St, Suite 205, 
Austin, TX 
 (5.9 miles away)
512-236-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nelly Velasquez is a primary care provider, practicing in Family Medicine in Austin, Texas. Dr. Velasquez is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia. Her top areas of expertise are Hepatitis A, Spastic Ataxia Charlevoix-Saguenay Type, Infantile-Onset Spinocerebellar Ataxia (IOSCA), and Behr Syndrome. Dr. Velasquez is currently accepting new patients.

Experienced in Spinocerebellar Ataxia
Dr. James P. Chudleigh
Geriatrics | General Practice
Experienced in Spinocerebellar Ataxia
Dr. James P. Chudleigh
Geriatrics | General Practice

Ascension Seton

300 S Commerce St, Suite B, 
Lockhart, TX 
 (34.0 miles away)
512-398-2331
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

James Chudleigh is a primary care provider, a Geriatrics specialist and a General Practice provider in Lockhart, Texas. Dr. Chudleigh is rated as a Distinguished provider by MediFind in the treatment of Spinocerebellar Ataxia. His top areas of expertise are Dementia, Alzheimer's Disease, Vascular Dementia, and Type 2 Diabetes (T2D). Dr. Chudleigh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Day's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 8 Distinguished Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile